Literature DB >> 3691743

Effect of oridonin, a Rabdosia diterpenoid, on radiosensitization with misonidazole.

C Murayama1, Y Nagao, S Sano, M Ochiai, K Fuji, E Fujita, T Mori.   

Abstract

The radiosensitization brought about by oridonin, one of the Rabdosia diterpenoids, alone or in combination with misonidazole, was investigated in Chinese hamster V79 cells. The enhancement ratio of 1.92 was obtained when 0.01 mM oridonin and 1 mM misonidazole were administered to hypoxic cells under radiation. The enhancement ratios of oridonin and misonidazole for hypoxic cells were 1.16 and 1.59 respectively. Hence, a supra-additive effect was obtained by the combined treatment with these two drugs. Under aerobic conditions, no effect of 0.01 mM oridonin on the radiosensitization caused by misonidazole was observed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691743     DOI: 10.1007/bf01945533

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  10 in total

1.  Antitumor activity of the Isodon diterpenoids: structural requirements for the activity.

Authors:  E Fujita; Y Nagao; M Node; K Kaneko; S Nakazawa; H Kuroda
Journal:  Experientia       Date:  1976-02-15

2.  The antitumor and antibacterial activity of the Isodon diterpenoids.

Authors:  E Fujita; Y Nagao; K Kaneko; S Nakazawa; H Kuroda
Journal:  Chem Pharm Bull (Tokyo)       Date:  1976-09       Impact factor: 1.645

Review 3.  Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy.

Authors:  S Dische
Journal:  Radiother Oncol       Date:  1985-02       Impact factor: 6.280

Review 4.  Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?

Authors:  R C Urtasun; C N Coleman; T H Wasserman; T L Phillips
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

5.  Antitumor activity of Rabdosia and Teucrium diterpenoids against P 388 lymphocytic leukemia in mice.

Authors:  Y Nagao; N Ito; T Kohno; H Kuroda; E Fujita
Journal:  Chem Pharm Bull (Tokyo)       Date:  1982-02       Impact factor: 1.645

6.  The use of drugs which deplete intracellular glutathione in hypoxic cell radiosensitization.

Authors:  E A Bump; N Y Yu; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

7.  Antitumor activity of acylated oridonin.

Authors:  E Fujita; Y Nagao; T Kohno; M Matsuda; M Ozaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1981-11       Impact factor: 1.645

8.  Glutathione depletion, radiosensitization, and misonidazole potentiation in hypoxic Chinese hamster ovary cells by buthionine sulfoximine.

Authors:  E P Clark; E R Epp; J E Biaglow; M Morse-Gaudio; E Zachgo
Journal:  Radiat Res       Date:  1984-05       Impact factor: 2.841

9.  Radiosensitization of hypoxic HeLa S3 cells in vitro by a new type of radiosensitizer: spermine and spermidine amides with nitro groups.

Authors:  C Murayama; Y Nagao; E Fujita; T Asao; M Yasumoto; T Mori
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1983-11

10.  Pharmacokinetics of hypoxic cell radiosensitizers: a review.

Authors:  P Workman
Journal:  Cancer Clin Trials       Date:  1980
  10 in total
  3 in total

1.  Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl-2.

Authors:  Sirui Li; Dan Shi; Liangyu Zhang; Fang Yang; Guanghui Cheng
Journal:  Exp Ther Med       Date:  2018-09-27       Impact factor: 2.447

2.  Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.

Authors:  Paul A Jackson; John C Widen; Daniel A Harki; Kay M Brummond
Journal:  J Med Chem       Date:  2016-12-20       Impact factor: 7.446

3.  Phytotherapeutics Oridonin and Ponicidin show Additive Effects Combined with Irradiation in Pancreatic Cancer in Vitro.

Authors:  Jakob Liermann; Patrick Naumann; Franco Fortunato; Thomas E Schmid; Klaus-Josef Weber; Jürgen Debus; Stephanie E Combs
Journal:  Radiol Oncol       Date:  2017-11-29       Impact factor: 2.991

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.